Delta Air Lines CEO Ed Bastian revealed that the new delta variant of Covid-19 hasn’t hurt their sales and that they are even getting 60 to 90 days of bookings in advance.
Bastian noted that the variant hasn’t impacted them and that they are learning to live with the health problem.
Summer travel and future travel bookings remain strong with domestic leisure travel surpassing 2019 levels before the pandemic.
Delta said that 72 percent of their employees and a “vast majority” of their customers are vaccinated.
Other airline CEOs, including those of American Airlines and United Airlines, also said that domestic leisure bookings have largely rebounded to 2019 levels and that business travel is also recovering, albeit at a much slower pace.
The delta variant became the dominant strain in the US earlier this month.


Yen Stabilizes Near Lows as Japan Signals Readiness to Intervene Amid Dollar Weakness
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Russian Stocks End Lower as Energy and Mining Shares Weigh on MOEX Index
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
BOJ Minutes Reveal Growing Debate Over Interest Rate Hikes and Inflation Risks
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
U.S. Stocks Rally to Record Highs as AI Rebound Fuels Holiday-Shortened Session
Italy Fines Apple €98.6 Million Over App Store Dominance
Japan Plans $189 Billion Bond Issuance as Record Budget Signals Expansionary Fiscal Policy
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Wall Street Ends Higher as S&P 500, Nasdaq Extend Gains Ahead of Holiday Week
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 



